Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Stifel 2025 ...

B. Riley has initiated coverage of Vanda Pharmaceuticals (VNDA) at buy saying that the company is currently trading at a ...

Fintel reports that on November 5, 2025, B. Riley Securities initiated coverage of Vanda Pharmaceuticals (NasdaqGM:VNDA) with ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ...

Shares of Vanda Pharmaceuticals fell after the company reported a third-quarter loss that wider than a year ago and dropped the high end of its full-year revenue view. The stock was 18% lower, at ...

Discover Vanda Pharmaceuticals' Q3 2025 results: strong Fanapt growth, updated guidance, and pipeline milestones.

With a win in a D.C. appeals court, Vanda Pharmaceuticals has earned a point over the FDA in the yearslong face-off between the drugmaker and the drug regulator. Vanda has been fighting to market its ...

Please provide your email address to receive an email when new articles are posted on . The FDA has issued a complete response letter to Vanda Pharmaceuticals indicating it cannot approve the ...

Vanda Pharmaceuticals has failed to persuade the FDA to approve its gastroparesis candidate on the strength of a phase 3 trial that missed its primary endpoint. The biotech came out swinging after the ...

The FDA’s rejection of Vanda Pharmaceuticals’ stomach disease candidate has done little to dampen the enthusiasm of England’s Cycle Pharmaceuticals to acquire the Washington D.C.-based company. On ...

On CNBC's "Mad Money Lightning Round," Jim Cramer discussed Apollo Global, National Fuel Gas, Main Street Capital and Vanda ...

The FDA has won a legal dispute with Vanda Pharmaceuticals over a partial clinical hold it imposed on tradipitant. Vanda took the FDA to court in the belief the agency's demand ran counter to ...